收费全文 | 135篇 |
免费 | 6篇 |
国内免费 | 6篇 |
儿科学 | 11篇 |
妇产科学 | 3篇 |
基础医学 | 8篇 |
口腔科学 | 2篇 |
临床医学 | 30篇 |
内科学 | 20篇 |
皮肤病学 | 2篇 |
神经病学 | 10篇 |
特种医学 | 19篇 |
外科学 | 24篇 |
综合类 | 10篇 |
预防医学 | 4篇 |
眼科学 | 1篇 |
药学 | 2篇 |
肿瘤学 | 1篇 |
2022年 | 1篇 |
2021年 | 3篇 |
2018年 | 8篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 5篇 |
2013年 | 3篇 |
2012年 | 5篇 |
2011年 | 2篇 |
2010年 | 5篇 |
2009年 | 10篇 |
2008年 | 7篇 |
2007年 | 7篇 |
2006年 | 18篇 |
2005年 | 3篇 |
2004年 | 1篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1998年 | 3篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1995年 | 3篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1968年 | 1篇 |
Purpose of Review
The goal of this review is to evaluate the global supply and demand of opioids used for pain management and discuss how it relates to the utilization of opioids around the world. The purpose of the review is also to determine the factors that contribute to inappropriate pain management.Recent Findings
The total global production of opium for opioid manufacturing is enough to supply the growing global demands. However, licit opioids are only consumed by 20% of the world population. Most people throughout the world had no access to opioid analgesics for pain relief in case of need. Opioid misuse and abuse is not only a phenomena plague by the USA but globally across many countries.Summary
Many countries have a lack of availability of opioids, contributing factors being strict government regulations limiting access, lack of knowledge of the efficacy of opioid analgesics in treating acute and chronic pain and palliative care, and the stigma that opioids are highly addictive. For the countries in which opioids are readily available and prescribed heavily, diversion, misuse, abuse, and the resurgence of heroin have become problems leading to morbidity and mortality. It is pertinent to find a balance between having opioids accessible to patients in need, with ensuring that opioids are regulated along with other illicit drugs to decrease abuse potential.Topical drug administration is commonly applied to control oral inflammation. However, it requires sufficient drug adherence and a high degree of bioavailability. Here, we tested the hypothesis whether an ester-based core-multishell (CMS) nanocarrier is a suitable nontoxic drug-delivery system that penetrates efficiently to oral mucosal tissues, and thereby, increase the bioavailability of topically applied drugs.
Material and methodsTo evaluate adhesion and penetration, the fluorescence-labeled CMS 10-E-15-350 nanocarrier was applied to ex vivo porcine masticatory and lining mucosa in a Franz cell diffusion assay and to an in vitro 3D model. In gingival epithelial cells, potential cytotoxicity and proliferative effects of the nanocarrier were determined by MTT and sulphorhodamine B assays, respectively. Transepithelial electrical resistance (TEER) was measured in presence and absence of CMS 10-E-15-350 using an Endohm-12 chamber and a volt-ohm-meter. Cellular nanocarrier uptake was analyzed by laser scanning microscopy. Inflammatory responses were determined by monitoring pro-inflammatory cytokines using real-time PCR and ELISA.
ResultsCMS nanocarrier adhered to mucosal tissues within 5 min in an in vitro model and in ex vivo porcine tissues. The CMS nanocarrier exhibited no cytotoxic effects and induced no inflammatory responses. Furthermore, the physical barrier expressed by the TEER remained unaffected by the nanocarrier.
ConclusionsCMS 10-E-15-350 adhered to the oral mucosa and adhesion increased over time which is a prerequisite for an efficient drug release. Since TEER is unaffected, CMS nanocarrier may enter the oral mucosa transcellularly.
Clinical relevanceNanocarrier technology is a novel and innovative approach for efficient topical drug delivery at the oral mucosa.
相似文献